Trial Profile
A Single Arm, Open-label Study of Early Improvement of Anemia and Fatigue During Treatment With Tocilizumab (TCZ) in Combination With DMARDs, in Adult Patients With Moderate to Severe Active Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Disease-modifying antirheumatics (Primary) ; Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- 08 Aug 2012 Actual patient number changed from 78 to 105 as reported by ClinicalTrials.gov record.
- 08 Aug 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 05 Dec 2011 Actual patient number changed from 45 to 78 as reported by ClinicalTrials.gov record.